GLP-1 Side Effects: Anecdotes vs. Clinical Evidence
PharmacologyComments
similar to hla-b*5701 screening for abacavir.
I wonder if the reports of sight loss... could be linked to the rapid shifts in blood glucose levels rather than the drug itself... that would be a fascinating distinction to map out!
FAERS data is notoriously noisy. The signal for NAION is likely skewed by the massive spike in off-label cosmetic use, which introduces a completely different patient demographic than the original trials.
The distinction regarding the malar fat pads is critical. Rapid adipose tissue depletion often outpaces the skin's ability to remodel its collagen matrix, a phenomenon seen in bariatric surgery patients long before GLP-1s existed.
Suppose there is a specific genetic predisposition that makes certain individuals susceptible to these ocular issues. Could these anecdotal reports actually be a signal for a small, high-risk subgroup that a standard clinical trial might underpower?
If a specific subgroup exists, do you think we could eventually develop a screening tool to identify those risks before a patient starts the medication?
Clinical trials wouldn't miss a signal if the effect size were actually significant. This is just availability bias playing out in real time; a few viral stories are being mistaken for a systemic trend.
All this debate actually helps people in the clinic. It pushes providers to actually monitor ocular health and vitals instead of just treating these as lifestyle scripts.